New Sanofi drug lowers LDL three times more than Zetia!

[Anonymous]

Phase III trials showed a 47% reduction in LDL-C. There was a high rate of adverse events with 69% experiencing side effects (most common problem was infection). Sounds like the next candidate for 1-800-bad-drug!

More precisely:

"The percentage of patients who reported treatment emergent adverse events was 78.4% in the ezetimibe group and 69.2% in the alirocumab group. The most common class of adverse events was infections (39.2% with ezetimibe vs. 42.3% with alirocumab), which included nasopharyngitis, influenza, and upper respiratory tract infection. Injection-site reactions occurred in less than 2% of patients in both groups. Muscle-related adverse events occurred in 3.9% of patients treated with ezetimibe and 3.8% of patients treated with alirocumab."

Not sure what point you are making actually. Isn't ezetimibe a Merck drug selling $2B? Which drug should we use that hotline number for?

 

[Anonymous]

Phase III trials showed a 47% reduction in LDL-C. There was a high rate of adverse events with 69% experiencing side effects (most common problem was infection). Sounds like the next candidate for 1-800-bad-drug!

You didn't read the study, did you. The rates of a/e' s in placebo was higher. And those scary infections you referred to were upper respiratory infection, nasopharyngitis and influenza. I've never read a drug label that didn't mention those a/e's.

These drugs are game changers, mark my words.

 

[Anonymous]

More precisely:

"The percentage of patients who reported treatment emergent adverse events was 78.4% in the ezetimibe group and 69.2% in the alirocumab group. The most common class of adverse events was infections (39.2% with ezetimibe vs. 42.3% with alirocumab), which included nasopharyngitis, influenza, and upper respiratory tract infection. Injection-site reactions occurred in less than 2% of patients in both groups. Muscle-related adverse events occurred in 3.9% of patients treated with ezetimibe and 3.8% of patients treated with alirocumab."

Not sure what point you are making actually. Isn't ezetimibe a Merck drug selling $2B? Which drug should we use that hotline number for?

Looks like it was flu season during the study.

 

[Anonymous]

Zetia is, at best, a do-nothing drug that is potentially harmful. No physician that's done his homework would ever recommend it to a patient.

 

[Anonymous]

Zetia is, at best, a do-nothing drug that is potentially harmful. No physician that's done his homework would ever recommend it to a patient.

Fortunately for us many physicians don't do any homework. Zetia + Vytorin + ~$4B. You go sales and marketing.

 

[Anonymous]

Zetia is, at best, a do-nothing drug that is potentially harmful. No physician that's done his homework would ever recommend it to a patient.

You are full of shit..zetia does what it is supposed to do at qd dosing..this new one is an injectable full of side effects with numerous other non pharmacologic effects! Zetia is a great adjunct to a statin, this one is not! Zetia had one stupid CIMT study and every oddball lawyer wannabe started chomping about it not working! Zetia does everything it is supposed to do and more, safe, well tolerated and every other wonder drug will have to pass the same tests now! You personally should be taking Niaspan & Lopid! Good luck bitch!

 

[Anonymous]

As Hillary said "What difference does it make?". All CV drugs (Zetia included) go generic by the end of 2016, This drug will not launch until then.